What are the progress and trend of China's class 1 chemical drug when the "13th Five-Year Plan" is closed? (lower)

TextsSun Xiangyu through the "13th Five-Year Plan" to close the official, China's class 1 chemical new drug progress and trend? We understand that, after the "13th Five-Year Plan" period of efforts, China's first class of chemical drugs research and development has a solid foundationOn this basis, the "14th Five-Year Plan" chemical new drug development will usher in greater development opportunities, and will present the following industry trendsWith the industrialization, urbanization, the progress of population aging and the changes of ecological environment and lifestyle, chronic non-communicable diseases have become the main causes of death and disease burden of our residents, and chronic noncommunicable diseases such as cardiovascular disease, cancer, chronic respiratory disease and diabetes account for 88% of the total death sonofing deaths in ChinaAt the same time, hepatitis, tuberculosis, AIDS and other major infectious diseases prevention and control situation is still serious, endemic diseases, parasitic diseases and other still serious lying at the health of the population in endemic areasThe United Nations Agenda for Sustainable Development 2030 has made the reduction of premature mortality from these four major chronic diseases an important development goalThe outline of the "Healthy China 2030" plan also incorporates this goal into the main indicators of healthy China constructionTherefore, from the perspective of clinical needs, the future research and development of 1 class of chemical innovation drugs in China will be mainly concentrated in the field of malignant tumors, cardiovascular diseases, diabetes and respiratory diseases and other chronic diseases; The top 30 "bomb-heavy" drugs in the global sales rankings typically have 40 to 60 percent effectivenessFor the vast majority of drugs, about 1/3 can not achieve satisfactory results, about 1/6 of the occurrence of different degrees of adverse reactions, the total safety efficiency of only about 50%At present, adverse drug reactions have become the fifth leading cause of death in humansTherefore, according to the genetic information carried by the individual to develop the medical model of personalized prevention, diagnosis and treatment plan for the individual, which is a revolution brought about by the development of genetic pharmacology and pharmacogenomicsBiomarkers are molecular markers that determine the efficacy of a drug, evaluate disease treatment response sorokes and prognosisIt can be used to predict disease (individual disease sensitivity prediction), early diagnosis of disease, judge drug efficacy and assess patient prognosisIn recent years, some of the top multinational pharmaceutical companies, including Genentech, Novartis and Pfizer, have adopted biomarker-driven new drug development models, given the drawbacks of traditional modelsThis model in clinical trials, combined with the role of the compound target, to find the most suitable compound to play the efficacy of the target population biomarkers, so as to accurately design clinical trial into the group conditions, optimize the test design, accelerate the progress of the trial, greatly improve the efficiency and success rate of new drug developmentOpen innovation has become the mainstream trend of pharmaceutical research and developmentPharmaceutical companies receive complementary resources (funds, new drug research and development technology, new drug research and development platform, production and origin, etc.) from outside, shorten research and development time, reduce research and development and production costs, and accelerate the entry of innovative drugs into the marketA growing number of open innovation models, such as joint research and development, licensing, mergers and acquisitions, joint ventures (JVs), corporate venture capital (CVC), academic centers, incubators, etc., are being used by innovative drug research and development companies, and cutting-edge models such as crowdsourcing, built-to-buy and virtual pharmaceutical companies (VPNs) are being actively exploredIn general, large pharmaceutical companies use external innovation tools to solve drug development problems, while small biotechnology companies use external innovation tools to address drug development and commercializationSome of the mergers and joint ventures of domestic pharmaceutical companies have involved overseas players, such as the acquisition of Celgene's China business, the joint venture between Beda Pharmaceuticals and Amgen, and the joint venture between Chihuang Pharmaceuticals and Nestle Health ScienceExternal innovation interactionhas have become a mainstream trendWhile focusing on the domestic market, Chinese biotech companies are also eager to break into the global marketOn the one hand, China's innovative pharmaceutical companies continue to accelerate domestic research and development market, on the other hand, also strive to expand overseas markets, there are a number of enterprises have carried out overseas multi-center clinical trials, "China-U.Sdouble report" has become an important strategy for domestic enterprises to carry out research and development of new drugsFrom the geographical distribution of the headquarters of the "China-U.SDouble Newspaper", Shanghai and Jiangsu enterprises (a total of 30) account for 60% of all enterprisesHengrui Pharma has 7 products in both China and the United States at the same time to carry out clinical trials, is the largest number of dual-reported varieties in China and the United States, followed by Fosun Pharma, there are 6 varieties of Sino-American double-reporting, Asia-Sheng Pharmaceutical performance is very eye-catching, the leader in non-listed companies, 5 products at the same time obtained clinical approval in China and the United StatesChina's biopharmaceutical industry from the tracking imitation stage (1950s-1990s), imitation innovation stage (1990s-2020s) to the original innovation stage (2020s - the future)Although during the "13th Five-Year Plan" period, China emerged Rosasta, Zebutinib and other innovative products, but on the whole, China's first class of new chemical drugs for foreign new drugs have been followed up (follow on), mostly me-too or me-better and other rapid imitation of innovative varieties, although these new drugs have new chemical structure and independent intellectual property rights, but its research and development ideas are still established in foreign countries have found the role of targets and mechanismsEmerging disciplines such as life groupscience, systems biology, structural biology, mathematical and information science (such as high-performance computing and data analysis) methods and technologies, deeply integrated into drug research and development, have led to new strategies, new methods and new technologies for drug research and developmentWith the continuous improvement of the domestic innovation ecology, the future of China's independent discovery of new targets of drug action, new mechanisms and the development of first in class new drugs will emerge in bulk, China's innovative drug research and developed countries significantly narrowed the gap, the birth of a number of enterprises with international influence.